Survival of lung cancer patients treated with BCG and/or a soluble BCG fraction (F70) after surgery, radiotherapy and chemotherapy.
243 lung cancer patients treated with routine therapy (surgery 54, radiotherapy 46 and chemotherapy 143) in Plovdiv's District Oncologic Dispensary (PDOD) were submitted to an additional therapy with BCG or with its soluble fraction F70. The survival rate of these patients was compared with the survival rate of 305 lung cancer patients following routine therapy alone (surgery 78, radiotherapy 113 and chemotherapy 114). The two groups were not randomized. Between patients treated and non-treated with BCG(F70) a significant increase of the survival rate was found for patients submitted to BCG(F70) treatment after surgery or radiotherapy in the 2nd and 3rd year survival period and for patients submitted to BCG(F70) treatment after chemotherapy -- in the 1st year survival period of patients with limited disease only. The effect of the additional BCG(F70) treatment was less dependent on the preceding routine therapy than upon the clinical stage of the disease at the moment of BCG(F70) treatment beginning. More salient results were observed in patients with undifferentiated histological forms.
D001500:BCG Vaccine / Q000627:therapeutic use*; D002454:Cell Differentiation; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D009367:Neoplasm Staging; D013997:Time Factors
D001500:BCG Vaccine